CFO
ABCL icon

CVA Family Office’s AbCellera Biologics ABCL Stock Holding History

CVA Family Office’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-339
Closed -$993 – 1388
2024
Q4 		$993 Buy
+339
New +$944 ﹤0.01% 1094
2024
Q2 		– Sell
-230
Closed -$1.04K – 1276
2024
Q1 		$1.04K Hold
230
– – ﹤0.01% 998
2023
Q4 		$1.31K Buy
+230
New +$1.07K ﹤0.01% 952

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CVA Family Office's ABCL Position: Q1 2025 in Review

CVA Family Office sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 339 shares — an estimated $993 sold.

CVA Family Office first reported a position in ABCL in Q4 2023 and held it in 3 quarters. The position peaked at $1.31K in Q4 2023. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

  • CVA Family Office reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
  • CVA Family Office sold 339 AbCellera Biologics shares in Q1 2025, an estimated $993.
  • CVA Family Office first reported a position in AbCellera Biologics in Q4 2023 and held it in 3 quarters.
  • CVA Family Office's AbCellera Biologics position peaked at $1.31K in Q4 2023.
  • 129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on CVA Family Office's 13F filing for Q1 2025, filed 16 Apr 2025.